Actively Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Led by Revolution Medicines, Inc. · Updated on 2026-05-14
900
Participants Needed
3
Research Sites
155 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
CONDITIONS
Official Title
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 18 years old and has provided informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Histologically or cytologically confirmed pancreatic adenocarcinoma
- Diagnosis of metastatic disease 6 weeks or less before informed consent
- Documented RAS mutation status, either mutant or wild-type
- Measurable disease according to RECIST v1.1
- Adequate organ function including bone marrow, liver, kidney, and coagulation
- Able to take oral medications
You will not qualify if you...
- Prior systemic anticancer therapy in metastatic setting or prior RAS-targeted therapy in any setting
- Active or history of untreated central nervous system metastatic disease
- Any condition affecting ability to take or absorb study drug
- Major surgery within 28 days before randomization
- Unable or unwilling to comply with study visits or procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
2
Comprehensive Cancer Centers of Nevada
Henderson, Nevada, United States, 89052
Actively Recruiting
3
Taylor Cancer Research Center
Maumee, Ohio, United States, 43537
Actively Recruiting
Research Team
R
Revolution Medicines Study Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here